Literature DB >> 17984630

Tolerability and efficacy of aripiprazole in a case of psychotic anorexia nervosa comorbid with epilepsy and chronic renal failure.

M Aragona1.   

Abstract

INTRODUCTION: The aim of this case report was to examine the therapeutic benefit and tolerability of aripiprazole for psychotic symptoms in a case of anorexia nervosa comorbid with generalized epilepsy, chronic renal failure and Raynaud syndrome. CASE REPORT: The patient had a chronic anorexia nervosa with psychotic symptoms, already treated with risperidone without efficacy, mainly because it was underdosed due to side-effects. She refused to take olanzapine (fear of weight gain) but accepted a treatment with aripiprazole. Aripiprazole 30 mg/day was associated with considerable improvement of SANS and SAPS (scale for the assessment of negative and positive symptoms) scores on hallucinations, delusions, aggressivity, abulia and asociality. Weight remained stable and no side-effects were reported. DISCUSSION: These findings lend support to the possibility that aripiprazole may be useful and well tolerated in psychotic anorexia and in cases of comorbidity with epilepsy and/or renal failure. These data are preliminary and need to be confirmed in further controlled research.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17984630     DOI: 10.1007/BF03327643

Source DB:  PubMed          Journal:  Eat Weight Disord        ISSN: 1124-4909            Impact factor:   4.652


  18 in total

1.  Risperidone in anorexia nervosa.

Authors:  J Newman-Toker
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2000-08       Impact factor: 8.829

2.  Psychiatric comorbidities of female inpatients with eating disorders.

Authors:  Barton J Blinder; Edward J Cumella; Visant A Sanathara
Journal:  Psychosom Med       Date:  2006 May-Jun       Impact factor: 4.312

3.  Body composition, cardiovascular and renal function in adolescent patients with anorexia nervosa.

Authors:  L Fohlin
Journal:  Acta Paediatr Scand Suppl       Date:  1977

4.  Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa.

Authors:  Naresh Mondraty; C Laird Birmingham; Stephen Touyz; Viktoria Sundakov; Lucy Chapman; Pierre Beumont
Journal:  Australas Psychiatry       Date:  2005-03       Impact factor: 1.369

5.  Increased cutaneous vasoreactivity to cold in anorexia nervosa.

Authors:  P Luck; A Wakeling
Journal:  Clin Sci (Lond)       Date:  1981-11       Impact factor: 6.124

6.  Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms.

Authors:  Jean Y Zhang; Dianne M Kowal; Stanley P Nawoschik; Zhuangwei Lou; John Dunlop
Journal:  Biochem Pharmacol       Date:  2005-12-05       Impact factor: 5.858

7.  A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.

Authors:  Robert D McQuade; Elyse Stock; Ron Marcus; Darlene Jody; Neveen A Gharbia; Simon Vanveggel; Don Archibald; William H Carson
Journal:  J Clin Psychiatry       Date:  2004       Impact factor: 4.384

8.  An open trial of olanzapine in anorexia nervosa.

Authors:  Nicole C Barbarich; Claire W McConaha; Jill Gaskill; Maria La Via; Guido K Frank; Sarah Achenbach; Katherine H Plotnicov; Walter H Kaye
Journal:  J Clin Psychiatry       Date:  2004-11       Impact factor: 4.384

9.  Psychosis in anorexia nervosa and bulimia.

Authors:  J I Hudson; H G Pope; J M Jonas
Journal:  Br J Psychiatry       Date:  1984-10       Impact factor: 9.319

10.  An open-label study of quetiapine in anorexia nervosa.

Authors:  P Bosanac; S Kurlender; T Norman; K Hallam; K Wesnes; T Manktelow; G Burrows
Journal:  Hum Psychopharmacol       Date:  2007-06       Impact factor: 1.672

View more
  3 in total

1.  The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa.

Authors:  Guido K W Frank; Megan E Shott; Jennifer O Hagman; Marissa A Schiel; Marisa C DeGuzman; Brogan Rossi
Journal:  Int J Eat Disord       Date:  2017-03-23       Impact factor: 4.861

2.  A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study.

Authors:  Jennifer Hagman; Jane Gralla; Eric Sigel; Swan Ellert; Mindy Dodge; Rick Gardner; Teri O'Lonergan; Guido Frank; Marianne Z Wamboldt
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2011-08-05       Impact factor: 8.829

Review 3.  Transient psychosis in anorexia nervosa: review and case report.

Authors:  S Sarró
Journal:  Eat Weight Disord       Date:  2009 Jun-Sep       Impact factor: 4.652

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.